STOCKS TELEGRAPH

Tag: Keros

  • Keros Therapeutics (KROS) Stock Gains Momentum In Pre-Hour Trading

    Keros Therapeutics (KROS) Stock Gains Momentum In Pre-Hour Trading

    After announcing that it will begin a formal evaluation of strategic options, Keros Therapeutics, Inc. (NASDAQ: KROS) saw a significant increase in pre-market trading, with its shares rising 13.55% to $11.73. KROS revealed that a comprehensive assessment with the goal of optimizing stockholder value has been approved by its Board of Directors.

    Commencement of the Comprehensive Strategic Assessment

    The Board of Keros Therapeutics has established a special Strategic Committee with independent and impartial directors to spearhead this effort. This group will investigate a broad range of strategic options with the assistance of outside financial and legal consultants. A corporate merger, a possible sale of the firm, more investment in its development pipeline, or the distribution of surplus funds to shareholders are a few examples.

    Transparency and Value Creation

    Keros Therapeutics stressed that while keeping its attention on operational performance, the strategic review is a component of its continuous commitment to increase shareholder value. KROS intends to give a preliminary update on the procedure within two months. Beyond this period, the company does not intend to make further public comments unless it deems such communication necessary or appropriate.

    Adoption of Stockholder Rights Plan

    Concurrently, Keros Therapeutics said that a limited-duration shareholder rights plan will be adopted, with immediate effect. A number of investors, including one who revealed an 11.2% position as of April 6, 2025, and stated ambitions to influence corporate governance, made this decision in response to recent, rapid accumulations of business shares.

    Safeguarding Fair Process and Stockholder Interests

    By discouraging any possible attempts to acquire control of KROS through open-market transactions without providing a reasonable premium, the rights plan aims to safeguard investors’ interests during the strategic review. Crucially, the strategy does not exclude the Board from interacting with reliable parties or taking into account valid suggestions that support Keros’ long-term worth and the interests of all parties involved.

    Investors’ focus is on the possible outcomes that might influence Keros Therapeutics’ future course as it sets out on its strategic journey.

  • Keros Therapeutics, Inc. (KROS) Stock Trending Lower Despite Success of Phase 2 Clinical Trial of KER-050

    Keros Therapeutics, Inc. (KROS) stock prices were down by 11.98% shortly after market trading commenced on June 23rd, 2021, bringing the price per share down to USD$46.28.

    Success of Phase 2 Trial

    June 22nd, 2021 saw the company announce preliminary results rom Cohorts 1 and 2 of its Phase 2 clinical trial. The trial is designed to evaluate KER-050 for the treatment of anemia and thrombocytopenia in patients with very low- to intermediate-risk myelodysplastic syndromes. Patients may or may not have ring sideroblasts and may or may not have been previously treated with an erythroid stimulating agent.

    Details of the Trial

    The ongoing trial is an open-label, two-part, multiple ascending dose trial that is designed to assess the trial’s safety, tolerability, pharmacokinetics, and pharmacodynamics of the treatment in MDS patients. 12 patients had received at least one dose of the treatment as of May 14th, 2021, 9 of whom had been administered the treatment for a period of 8 weeks. Patients in Cohort 1 were administered 0.75mg/kg of KER-050, while Cohort 2 patients received 1.5 mg/kg. Both cohorts were treated once every four weeks for 12 weeks.

    Scope of KER-050

    The preliminary results were promising, with increases being observed in hematological parameters in the two lowest Part 1 dose cohorts, who were dosed monthly, in both RS and non-RS patients with MDS. This initial success signals proof-of-concept of the treatment in patients with very low- to intermediate-risk MDS, which support the scope of KER-050 as a treatment for disease associated with ineffective hematopoiesis.

    Expansion of Trial

    Furthermore, based on the success of the preliminary results, the company plans to extend the duration of the trial from 12 weeks to up to two years. This is to better facilitate the defining of response rate following six months of treatment with KER-050, as well as to confirm the durability of response. KROS also plans to update the protocol to expand the size of Part 2 of the trial to consolidate response rates, as well as to help guide the design of the expected registration program. Part 2 trial designs are expected by the end of 2021.

    Future Outlook for KROS

    Armed with the success of its clinical trial, KROS is poised to capitalize on the opportunities afforded to it to push for the commercialization and proliferation of KER-050. The company is keen to usher in further growth with the potential of its expanded footprint. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.